Bronchiectasis Treatment Guidelines

Acute Exacerbation Treatment

The European Respiratory Society strongly recommends 14 days of antibiotic therapy for all acute exacerbations, with antibiotic selection based on previous sputum culture results, regardless of severity 1, 2
For Pseudomonas aeruginosa infections, ciprofloxacin 500mg twice daily is recommended for the full 14-day course 3
For Haemophilus influenzae or Streptococcus pneumoniae, amoxicillin is first-line for 14 days 2
Intravenous antibiotics should be considered for severe exacerbations or treatment failures, maintaining the 14-day duration 4
A pediatric trial demonstrated that amoxicillin-clavulanate was superior to placebo at resolving symptoms after 14 days, and also significantly reduced exacerbation duration 5

Long-term antibiotics should only be initiated after patients experience ≥3 exacerbations per year, following optimization of airway clearance techniques and treatment of underlying causes 1, 2, 4
The European Respiratory Society recommends a minimum of 6 months of long-term macrolide therapy with regular reassessment to determine ongoing clinical benefit 5
The EMBRACE study used azithromycin for 6 months and demonstrated significant reduction in exacerbations (RR 0.38, 95% CI 0.26–0.54) 6
Studies of inhaled antibiotics evaluated treatment durations of 6-12 months with demonstrated efficacy 6
Children and adolescents receiving treatment courses exceeding 24 months should continue to be evaluated for risk versus benefit 5

Long-term mucoactive treatment should be continued for ≥3 months in patients with difficulty expectorating sputum and poor quality of life where standard airway clearance techniques have failed 1, 7, 2

Before initiating long-term antibiotics, exclude active nontuberculous mycobacterial (NTM) infection, as macrolide monotherapy increases macrolide resistance in NTM 1, 5
During long-term antibiotic therapy, perform regular sputum culture and sensitivity monitoring to track resistance patterns and identify treatment-emergent organisms 1, 4
Drug toxicity monitoring, particularly with macrolides and inhaled aminoglycosides, should be performed 1, 4
Supervised test dose with pre- and post-spirometry for inhaled antibiotics due to 10-32% risk of bronchospasm 1

The guidelines do not specify explicit criteria for discontinuing long-term antibiotics beyond the recommendation for regular reassessment of clinical benefit 5, 4
Consider discontinuation if exacerbation frequency decreases to <3 per year consistently, significant adverse effects or resistance patterns emerge, or loss of clinical benefit despite adequate adherence 1, 5